Dermatology Update 2017 Fall



EXPOSED: Uncovering the Facts about Psoriasis Management with IL-17 Inhibitors


The overarching goal of this session is to highlight the importance of treatment optimization, to increase awareness of emerging therapies and to improve the care of patients with moderate to severe psoriasis.


The session will serve as a vehicle to reinforce awareness and understanding of the mode of action of IL-17 inhibitors, their efficacy, key benefits, and safety considerations. The program will be highly interactive to promote in-depth discussion on the subject matter and designed to test current knowledge and promote reflection. The session will incorporate short data presentations, panel discussions and participant polling questions.

Upon completion of this activity, participants will be able to:

  1. Discuss the role for IL-17 inhibitors, including treatment optimization.
  2. Evaluate and assess new clinical trial data regarding the efficacy and safety profiles of biologics targeting the IL-17 pathway.
  3. Apply practical approaches to using IL-17 inhibitors in daily practice.


Time Topic Speakers
11:00-11:10 Introduction Dr. Marc Bourcier
11:10-11:25 Treatment gaps and unmet needs Dr. Chih-ho Hong
11:25-11:30 Panel discussion Led by Dr. Marc Bourcier
11:30-11:45 IL-17 efficacy, new data Dr. Melinda Gooderham
11:45-11:50 Panel discussion Led by Dr. Marc Bourcier
11:50-12:05 IL-17 safety and practical considerations Dr. Marni Wiseman
12:05-12:10 Panel discussion Led by Dr. Marc Bourcier
12:10-12:15 Closing remarks Dr. Marc Bourcier


Dr. Marc Bourcier

Dr. Marc Bourcier

Dermatologist, Moncton, NB

Dr. Chih-Ho Hong

Dr. Chih-Ho Hong

Dermatologist, Surrey, British Columbia

Dr. Melinda Gooderham

Dr. Melinda Gooderham

Dermatologist, Peterborough, ON

Dr. Marni Wiseman

Dr. Marni Wiseman

Dermatologist, Winnipeg, MB

Part of the Event

Missing Event Data